Last reviewed · How we verify
COX-2 inhibitor
COX-2 inhibitor is a COX-2 selective inhibitor Small molecule drug developed by Seoul National University Hospital. It is currently in Phase 3 development for Rheumatoid arthritis, Osteoarthritis, Acute pain. Also known as: EtoriCoxib.
COX-2 inhibitors selectively block cyclooxygenase-2 enzyme to reduce prostaglandin production and inflammation without significantly affecting COX-1-mediated gastric protection.
COX-2 inhibitors selectively block cyclooxygenase-2 enzyme to reduce prostaglandin production and inflammation without significantly affecting COX-1-mediated gastric protection. Used for Rheumatoid arthritis, Osteoarthritis, Acute pain.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | COX-2 inhibitor |
|---|---|
| Also known as | EtoriCoxib |
| Sponsor | Seoul National University Hospital |
| Drug class | COX-2 selective inhibitor |
| Target | COX-2 (Cyclooxygenase-2) |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Pain Management |
| Phase | Phase 3 |
Mechanism of action
COX-2 is an inducible enzyme upregulated during inflammation and produces prostaglandins that drive pain, fever, and inflammatory responses. By selectively inhibiting COX-2 while sparing COX-1, these drugs reduce inflammatory prostaglandins while theoretically preserving the protective prostaglandins in the gastrointestinal tract. This selectivity was designed to provide anti-inflammatory and analgesic benefits with reduced GI toxicity compared to non-selective NSAIDs.
Approved indications
- Rheumatoid arthritis
- Osteoarthritis
- Acute pain
- Ankylosing spondylitis
Common side effects
- Cardiovascular events (myocardial infarction, stroke)
- Gastrointestinal ulceration
- Hypertension
- Edema
- Dyspepsia
Key clinical trials
- Clinical Evaluation of Arthrocentesis, Combination of Platelet-Rich Plasma and Cyclooxygenase Enzyme-2 Inhibitor in Treatment of Temporo-Mandibular Joint Anterior Displacement (PHASE3)
- Etoricoxib in Patients With Parkinsonian Disease (PHASE2)
- The Seven Trial: Exploiting the Unfolded Protein Response (PHASE1)
- Celecoxib in Parkinson Disease as Adjuvant Therapy (PHASE1, PHASE2)
- Novel PET Radioligand as an Inflammatory Biomarker in Musculoskeletal Conditions (PHASE1)
- Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer (PHASE2)
- Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC) (PHASE2)
- Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- COX-2 inhibitor CI brief — competitive landscape report
- COX-2 inhibitor updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI
Frequently asked questions about COX-2 inhibitor
What is COX-2 inhibitor?
How does COX-2 inhibitor work?
What is COX-2 inhibitor used for?
Who makes COX-2 inhibitor?
Is COX-2 inhibitor also known as anything else?
What drug class is COX-2 inhibitor in?
What development phase is COX-2 inhibitor in?
What are the side effects of COX-2 inhibitor?
What does COX-2 inhibitor target?
Related
- Drug class: All COX-2 selective inhibitor drugs
- Target: All drugs targeting COX-2 (Cyclooxygenase-2)
- Manufacturer: Seoul National University Hospital — full pipeline
- Therapeutic area: All drugs in Rheumatology / Pain Management
- Indication: Drugs for Rheumatoid arthritis
- Indication: Drugs for Osteoarthritis
- Indication: Drugs for Acute pain
- Also known as: EtoriCoxib
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing